Macugen (pegaptanib) is filed as Anti-VEGF (Intravitreal). The sections below restate public label fields stored for this profile.
1 INDICATIONS AND USAGE MACUGEN® (pegaptanib sodium injection) is indicated for the treatment of neovascular (wet) age-related macular degeneration. MACUGEN is indicated for the treatment of neovascular (wet) age-related macular degeneration ( 1 ).
12.1 Mechanism of Action Pegaptanib is a selective vascular endothelial growth factor (VEGF) antagonist. VEGF is a secreted protein that selectively binds and activates its receptors located primarily on the surface of vascular endothelial cells. VEGF induces angiogenesis, and increases vascular permeability and inflammation, all of which are thought to contribute to the progression of the neovascular (wet) form of age-related macular degeneration (AMD), a leading cause of blindness. VEGF has been implicated in blood retinal barrier breakdown and pathological ocular neovascularization. Pegaptanib is an aptamer, a pegylated modified oligonucleotide, which adopts a three-dimensional conformation that enables it to bind to extracellular VEGF. Under in vitro testing conditions, pegaptanib binds to the major pathological VEGF isoform, extracellular VEGF 165 , thereby inhibiting VEGF 165 binding to its VEGF receptors. The inhibition of VEGF 164 , the rodent counterpart of human VEGF 165 , was effective at suppressing pathological neovascularization.
5 WARNINGS AND PRECAUTIONS • Endophthalmitis may occur following intravitreous injections. Proper aseptic injection technique should always be utilized when administering MACUGEN. Patients should be monitored during the week following the injection. ( 5.1 ) • Increases in intraocular pressure have been seen within 30 minutes of injection of MACUGEN. ( 5.2 ) • Rare cases of anaphylaxis/anaphylactoid reactions, including angioedema, have been reported in the postmarketing experience. ( 5.3 ) 5.1 Endophthalmitis Intravitreous injections, including those with MACUGEN, have been associated with endophthalmitis. Proper aseptic injection technique should always be utilized when administering MACUGEN. In addition, patients should be monitored during the week following the injection to permit early treatment, should an infection occur [ see Dosage and Administration ( 2.4 ) ]. 5.2 Increases in Intraocular Pressure Increases in intraocular pressure have been seen within 30 minutes of injection with MACUGEN. Therefore, intraocular pressure as well as the perfusion of the optic nerve head should be monitored and managed appropriately [ see Dosage and Administration ( 2.4 ) ]. 5.3 Anaphylaxis Rare cases of anaphylaxis/anaphylactoid reactions, including angioedema, have been reported in the postmarketing experience following the MACUGEN intravitreal administration procedure [ see Dosage and Administration ( 2.4 ) and Adverse Events ( 6.3 ) ].
4 CONTRAINDICATIONS • Ocular or periocular infections ( 4.1 ). • Hypersensitivity ( 4.2 ). 4.1 Ocular or Periocular Infections MACUGEN is contraindicated in patients with ocular or periocular infections. 4.2 Hypersensitivity MACUGEN is contraindicated in patients with known hypersensitivity to pegaptanib sodium or any other excipient in this product.
6 ADVERSE REACTIONS Most common adverse reactions (reported in 10-40% of patients treated with MACUGEN for up to two years) are anterior chamber inflammation, blurred vision, cataract, conjunctival hemorrhage, corneal edema, eye discharge, eye irritation, eye pain, hypertension, increased intraocular pressure (IOP), ocular discomfort, punctate keratitis, reduced visual acuity, visual disturbance, vitreous floaters, and vitreous opacities ( 6.2 ). To report SUSPECTED ADVERSE REACTIONS, contact Bausch + Lomb, a division of Valeant Pharmaceuticals North America LLC, at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Injection Procedure Serious adverse events related to the injection procedure occurring in <1% of intravitreous injections included endophthalmitis [ see Warnings and Precautions ( 5.1 ) ], retinal detachment, and iatrogenic traumatic cataract. 6.2 Clinical Studies Experience The most frequently reported adverse events in patients treated with MACUGEN 0.3 mg for up to two years were anterior chamber inflammation, blurred vision, cataract, conjunctival hemorrhage, corneal edema, eye discharge, eye irritation, eye pain, hypertension, increased intraocular pressure (IOP), ocular discomfort, punctate keratitis, reduced visual acuity, visual disturbance, vitreous floaters, and vitreous opacities. These events occurred in approximately 10-40% of patients. The following events were reported in 6-10% of patients receiving MACUGEN 0.3 mg therapy: Ocular : blepharitis, conjunctivitis, photopsia, vitreous disorder. Non-Ocular : bronchitis, diarrhea, dizziness, headache, nausea, urinary tract infection. The following events were reported in 1-5% of patients receiving MACUGEN 0.3 mg therapy: Ocular : allergic conjunctivitis, conjunctival edema, corneal abrasion, corneal deposits, corneal epithelium disorder, endophthalmitis, eye inflammation, eye swelling, eyelid irritation, meibomianitis, mydriasis, periorbital hematoma, retinal edema, vitreous hemorrhage. Non-Ocular : arthritis, bone spur, carotid artery occlusion, cerebrovascular accident, chest pain, contact dermatitis, contusion, diabetes mellitus, dyspepsia, hearing loss, pleural effusion, transient ischemic attack, urinary retention, vertigo, vomiting. 6.3 Postmarketing Experience Anaphylaxis/anaphylactoid reactions, including angioedema, have been identified during postapproval use of MACUGEN. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure [ see Dosage and Administration ( 2.4 ) and Warnings and Precautions ( 5.3 ) ].
2 DOSAGE AND ADMINISTRATION • FOR OPHTHALMIC INTRAVITREAL INJECTION ONLY ( 2.1 ). • MACUGEN 0.3 mg should be administered once every six weeks by intravitreous injection into the eye to be treated ( 2.2 ). 2.1 General Dosing Information FOR OPHTHALMIC INTRAVITREAL INJECTION ONLY. 2.2 Dosing MACUGEN 0.3 mg should be administered once every six weeks by intravitreous injection into the eye to be treated. 2.3 Preparation for Administration MACUGEN should be inspected visually for particulate matter and discoloration prior to administration. If visible particulates are observed and/or the liquid in the syringe is discolored, the syringe must not be used. Administration of the syringe contents involves assembly of the syringe with the administration needle. The injection procedure should be carried out under controlled aseptic conditions, which includes the use of sterile gloves, a sterile drape, and a sterile eyelid speculum (or equivalent). When ready to assemble syringe and administer injection, carefully peel open pouches, remove contents, and place on sterile field. If upon opening the pouch, the plastic clip is missing or not attached to the syringe, the syringe should not be used. To avoid compromising the sterility of the product, do not pull back on the plunger. 1. Remove the syringe from the plastic clip. 2. Twist off cap. 3. Attach the sterile, single-use administration needle (included) to the syringe by screwing it into the syringe tip. --Another sterile, single-use administration needle may be used in lieu of the one included. Remove the plastic needle shield from the needle. 4. Holding the syringe with the needle pointing up, check the syringe for bubbles. If there are bubbles, gently tap the syringe with your finger until the bubbles rise to the top of the syringe. SLOWLY depress the plunger to eliminate all the bubbles and to expel the excess drug so that the top edge of the 3rd rib on the plunger stopper aligns with the preprinted black dosing line (see Figure 2, below) . 5. Inject the entire contents of the syringe. PRIOR to Injection Figure 1. Before expelling air bubble and excess drug READY for Injection Figure 2. After expelling air bubble and excess drug figure1.jpg figure2.jpg 2.4 Administration The injection procedure should be carried out under controlled aseptic conditions, which includes the use of sterile gloves, a sterile drape, and a sterile eyelid speculum (or equivalent). Adequate anesthesia and a broad-spectrum microbicide should be given prior to the injection. The patient's medical history for hypersensitivity reactions should be evaluated prior to performing the intravitreal procedure [ see Warnings and Precautions ( 5 ) and Adverse Events ( 6 ) ]. Following the injection, patients should be monitored for elevation in intraocular pressure and for endophthalmitis. Monitoring may consist of a check for perfusion of the optic nerve head immediately after the injection, tonometry within 30 minutes following the injection, and monitoring during the week following the injection. Patients should be instructed to report any symptoms suggestive of endophthalmitis without delay. No special dosage modification is required for any of the populations that have been studied (i.e. gender, elderly). The safety and efficacy of MACUGEN therapy administered to both eyes concurrently have not been studied.
According to its FDA label, Macugen (pegaptanib) is approved for: 1 INDICATIONS AND USAGE MACUGEN® (pegaptanib sodium injection) is indicated for the treatment of neovascular (wet) age-related macular degeneration. MACUGEN is indicated for the treatment of neovascular (wet) age-related macular degeneration ( 1 ). For medical advice, please talk to your prescriber or pharmacist.
Macugen (pegaptanib) belongs to the Anti-VEGF (Intravitreal) class of medications.
The FDA label lists Macugen (pegaptanib) as: 3 DOSAGE FORMS AND STRENGTHS Single-use glass syringe pre-filled with 0.3 mg of MACUGEN ® in a nominal 90 μL solution for intravitreal injection. • 0.3 mg/90 μL solution in a single-use syringe for intravitreal injection ( 3 ).. Available strengths and packaging vary by manufacturer.
Our ingest of the FDA label for Macugen (pegaptanib) does not include a Boxed Warning at this time. See the full label on DailyMed for the current, authoritative version.
Public CMS NADAC pricing for Macugen (pegaptanib) is in the range Retail prices vary widely by pharmacy, insurance, and location. Check with your pharmacy or use tools like GoodRx for current pricing.. Retail price varies by pharmacy, insurance, and manufacturer coupons.
The FDA Enforcement Report does not show an active/ongoing recall for Macugen (pegaptanib) in our latest ingest. Recall data can change daily — verify at FDA.gov.
The FDA label lists a pregnancy category of B for Macugen (pegaptanib). Pregnancy and lactation decisions should be made with a clinician.
Loading full data from Know Your Drugs Institute…